Iranian Firm Produces Drug to Treat Alzheimer's, Cancer without Harming Healthy Tissues

The company put the synthesis of Alzheimer's and glioma cancer drugs based on exosomes and nanoparticles on its agenda for research work.

The designed drug contains effective nanoparticles as antioxidants and anticancer agents for easy absorption in epithelial cells.

This drug platform is capable of targeted drug delivery and allows for unrestricted exosome transplantation.

Helping to treat the disease without causing allergies and other problems, targeted treatment without negative impacts on other cells and adjacent tissues, and gradual release and treatment of cells at risk of increased ROS levels are other advantages of the drug.

In a relevant development in December, Iranian researchers at a knowledge-based company had also produced a new and cost-effective nanomedicine for treating cancer patients.

“This drug plays an important role as an anti-tumor drug in the treatment of certain types of cancer and is used in the treatment of metastatic breast cancer, specially for the patients who have heart problems,” said Ahmad Pourahadi, the managing director of the company.

“The drug’s name is Sina Doxosome and it is also effective in the treatment of advanced ovarian cancer and acts as an important treatment option in reducing the growth and spread of cancer cells,” he added.

Noting that the drug is also applied as an effective solution in the treatment of Kaposi's sarcoma in patients with AIDS, Pourahadi said, “This product contains a drug that can selectively destroy cancer cells. The doxorubicin hydrochloride contained in this drug is surrounded by small liposomal spherical shells.”

“The concentration process in this drug allows the drug to be more effectively directed through the bloodstream to cancerous tissues,” he underlined.

4155/v